CAJ | 학술논문

目的：观察碳酸镧治疗血液透析患者高钙、高磷血症的有效性和安全性。方法选择28例存在高钙、高磷血症的维持性血液透析（maintenance hemodialysis，MHD）患者，每日3餐餐中予嚼服碳酸镧咀嚼片，治疗1，2，3个月后对血钙、血磷和 PTH 水平进行分析评估，并观察不良反应。结果患者口服碳酸镧治疗后血磷、钙磷乘积水平明显下降，而血清钙、甲状旁腺激素等指标在治疗前后并无明显变化（P ﹥0.05）。在服用碳酸镧过程中，无1例患者因严重的不良反应中断治疗。结论碳酸镧能够安全和有效地降低 MHD 患者的血磷及钙磷乘积水平。
목적：관찰탄산란치료혈액투석환자고개、고린혈증적유효성화안전성。방법선택28례존재고개、고린혈증적유지성혈액투석（maintenance hemodialysis，MHD）환자，매일3찬찬중여작복탄산란저작편，치료1，2，3개월후대혈개、혈린화 PTH 수평진행분석평고，병관찰불량반응。결과환자구복탄산란치료후혈린、개린승적수평명현하강，이혈청개、갑상방선격소등지표재치료전후병무명현변화（P ﹥0.05）。재복용탄산란과정중，무1례환자인엄중적불량반응중단치료。결론탄산란능구안전화유효지강저 MHD 환자적혈린급개린승적수평。
Objective:To assess the efficacy and side effects of lanthanum carbonate in maintenance hemodialysis (MHD)patients with hypercalcinemia and hyperphosphatemia. Methods:Twenty-eight MHD patients with hypercalcinemia and hyperphosphatemia were prescribed with lanthanum carbonate,three times a day in mealtime. Before and after using lan-thanum carbonate therapy for 1,2 and 3 months,the serum calcium,phosphorus and intact parathyroid hormone were meas-ured,and the side effects were also observed. Results:After treatment,serum phosphorus and calcium-phosphorus products decreased significantly(P ﹤ 0. 05). The serum calcium,and serum parathyroid hormone showed no obvious variation(P ﹥0. 05). The side effects of lanthanum carbonate were weak. No patient dropped therapy and no serious adverse events were observed. Conclusion:The management of hyperphosphatemia with lanthanum carbonate in MHD patients is safe and effec-tive.